Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene hunt: could DNA secrets unlock rhabdomyosarcoma prognosis?

NCT ID NCT03296371

Knowledge-focused Sponsor: Children's Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores genetic mutations in children with embryonal or alveolar rhabdomyosarcoma by analyzing saliva or cheek cell samples from the child and their parents. The goal is to identify inherited or new gene changes that may help doctors predict how the disease will progress. About 900 participants and their parents are involved, but this research does not test any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with embryonal or alveolar rhabdomyosarcoma enrolled on ACCRN07 and/or APEC14B1 and registered with Children's Oncology Group (COG)

Ages

Up to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must be enrolled on ACCRN07 and/or APEC14B1 and registered with COG by a North American member institution * The patient must have a diagnosis of embryonal rhabdomyosarcoma or alveolar rhabdomyosarcoma * The patient must be diagnosed with rhabdomyosarcoma between January 1, 2012 and November 30, 2019 * Concomitant treatment on a therapeutic trial is not required * The patient must have at least one biological parent alive and willing to participate * All questionnaire respondents must understand English or Spanish * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar rhabdomyosarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alveolar rhabdomyosarcoma embryonal rhabdomyosarcoma Rhabdomyosarcoma, Embryonal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar rhabdomyosarcoma Embryonal rhabdomyosarcoma

Contacts and locations

Locations

  • Childrens Oncology Group

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.